Drug Patent Watch
FEBRUARY 3, 2024
NATESTO (testosterone) Acerus Patent: 8,877,230 Expiration: Feb 4, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit… The post Drug Patent Expirations for the Week of February 4, 2024 appeared first on DrugPatentWatch - Make Better Decisions.
Velocity Clinical Research
FEBRUARY 3, 2024
To bring equitable products to market, clinical trials need proportionate representation. Reaching the right patients must be prioritized at the site level, where clinical research is most visible in communities. Therefore, Velocity is heavily invested in leveraging the power of local influence to drive change. Our focus is on managing what we can effectively control at the site level to foster a more inclusive and representative clinical trial landscape.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
FEBRUARY 3, 2024
Annual Drug Patent Expirations for NATESTO Natesto is a drug marketed by Acerus and is included in one NDA. It is available from one supplier. There are five patents protecting… The post New patent expiration for Acerus drug NATESTO appeared first on DrugPatentWatch - Make Better Decisions.
Clinical Trial Podcast
FEBRUARY 3, 2024
To learn more about clinical trials in diabetes, I invited Dr. Stayce Beck, Global Vice President of Clinical Affairs at Dexcom Inc. on the podcast. Dr. Beck currently oversees clinical operations, clinical strategy and science, biometrics and human factors at Dexcom Inc, a leading manufacturer of continuous glucose monitors (CGMs) Prior to joining Dexcom, Dr.
Drug Patent Watch
FEBRUARY 3, 2024
Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Sumitomo Pharma and is included in one NDA. It is available from one supplier. There are eight patents… The post New patent expiration for Sumitomo Pharma drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
FEBRUARY 3, 2024
Following a series of rejections and clinical failures, Eiger BioPharmaceuticals has declared bankruptcy and will sell all its assets as the company winds down operations.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
FEBRUARY 3, 2024
Following promising Phase IIa data, Vertex Pharmaceuticals will now evaluate its oral drug candidate inaxaplin in a late-stage study of APOL-1 mediated kidney disease.
BioSpace
FEBRUARY 3, 2024
A federal appeals court Monday backed Teva and Viatris’ challenge to a lower court ruling, finding that the companies can again make their case against Johnson & Johnson’s patent covering its schizophrenia drug Invega Sustenna.
Expert insights. Personalized for you.
64 
Let's personalize your content